ECONOMIC PROSPECT ANALYSIS

Intuitive Surgical Inc. (ISRG)

Forward-looking competitive assessment — compiled by Gemini 3.1

Strong Prospect

Monopoly in robotic surgery with 90%+ market share in soft tissue robotic procedures. The installed base of da Vinci systems creates a razor/blade model with recurring instrument revenue. Ion platform expands into lung biopsy.

View DCF Intrinsic Value Analysis →

Competitive Momentum

26/35

Moat Durability

30/35

Sentiment & Catalysts

22/30

🚀 Key Catalysts

Da Vinci 5 driving system upgrades and expanding the addressable procedure set beyond current 7M annual procedures
Ion bronchoscopy platform reaching inflection point for lung cancer screening, addressing a $5B+ TAM
Procedure growth in emerging markets (China, India) where robotic surgery penetration is under 5%

⚠️ Key Risks

Medtronic Hugo and J&J Ottava robotic surgery platforms gaining regulatory clearances and offering lower-cost alternatives
Hospital capital budgets tightening in a recession, delaying new system purchases
Da Vinci 5 transition creating short-term revenue headwinds as customers pause orders to wait for the new platform

Methodology

Score is based on three pillars: Competitive Momentum (0-35), Moat Durability (0-35), and Sentiment & Catalysts (0-30), totaling 0-100. Each pillar is broken into individually scored factors with transparent rationale. Data sources include FY2025 10-K filings, analyst consensus estimates, news sentiment analysis, and competitive landscape assessment. The score is forward-looking and represents economic prospect over a 2-3 year horizon.

Disclaimer: This economic prospect score is for educational purposes only. It is generated by an AI model (Gemini 3.1) based on publicly available data and may not reflect all material factors. This does not constitute investment advice. Always conduct your own due diligence.